Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

56.48 +0.91 (+1.64%)

Official Closing Price Updated: 4:10 PM EDT, Jun 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

69 70 Next >

Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500? ↗

June 08, 2026

For a solid yield and strong upside potential, this pharmaceutical stock is worth considering.

Via The Motley Fool

Topics Intellectual Property Stocks

Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock ↗

June 05, 2026

What does this smart money investor see that the market is missing?

Via The Motley Fool

Topics Intellectual Property

Bristol-Myers Squibb Co (NYSE:BMY): High Yield and Solid Profitability, but Growth Concerns Loom ↗

June 05, 2026

Via Chartmill

Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer? ↗

June 04, 2026

Durability, not yield, is the deciding factor.

Via The Motley Fool

Bristol Myers Squibb (NYSE:BMY) Q1 2026 Earnings Beat Driven by Growth Portfolio ↗

April 30, 2026

Via Chartmill

Topics Earnings

3 Value Stocks We Think Twice About

June 04, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Via StockStory

Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? ↗

June 03, 2026

Whichever one you choose, you'll need patience before you can see solid returns.

Via The Motley Fool

Topics Intellectual Property

Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks ↗

June 01, 2026

Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.

Via The Motley Fool

Topics Intellectual Property

Explore the top gainers and losers within the S&P500 index in today's session. ↗

June 01, 2026

Via Chartmill

Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1

May 31, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Surging Stock with Promising Prospects and 2 We Ignore

May 25, 2026

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...

Via StockStory

Looking to Buy Bristol Myers Squibb Stock on the Dip? Read This First. ↗

May 24, 2026

The numbers don't tell the full story with this big pharma stock.

Via The Motley Fool

Topics Intellectual Property

The Most Undervalued Healthcare Stock in the S&P 500 Right Now ↗

May 21, 2026

The market appears to be short-sighted.

Via The Motley Fool

Topics Intellectual Property Stocks

1 Profitable Stock to Keep an Eye On and 2 We Brush Off

May 21, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Via StockStory

Topics Energy

3 High-Yielding Dividend Stocks Trading at Dirt Cheap Valuations ↗

May 18, 2026

These stocks are facing adversity, but with high yields and cheap valuations, investors may be compelled to take a chance on them.

Via The Motley Fool

10 Years Later: 5 Winners in a Thinking World ↗

May 13, 2026

What happens when you actually do the thing most investors only talk about and hold stocks for a full decade?

Via The Motley Fool

2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down

May 13, 2026

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...

Via StockStory

Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?

May 12, 2026

Bristol-Myers Squibb has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $55.77, markin...

Via StockStory

Topics Stocks

Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗

May 11, 2026

This may be an excellent deal for those focused on the long game.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting ↗

May 10, 2026

Bristol Myers Squibb (NYSE:BMY) used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives,...

Via MarketBeat

Bristol-Myers Squibb’s Q1 Earnings Call: Our Top 5 Analyst Questions

May 07, 2026

Bristol-Myers Squibb’s first quarter results were notably shaped by ongoing momentum in its growth portfolio and steady execution across key marketed product...

Via StockStory

Topics Earnings

1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges

May 06, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged...

Via StockStory

BMY Q1 Deep Dive: Growth Portfolio, Pipeline Milestones, and Anticipated Late-Stage Readouts

May 01, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q1 CY2026, with sales up 2.6% year on year to $11.49 bill...

Via StockStory

Why Bristol Myers Squibb Stock Rocked the Market Today ↗

April 30, 2026

It scored crushing beats on both revenue and profitability in its first quarter.

Via The Motley Fool

Bristol Myers (BMY) Q1 2026 Earnings Transcript ↗

April 30, 2026

Bristol Myers (BMY) Q1 2026 Earnings Transcript

Via The Motley Fool

Bristol-Myers Squibb (NYSE:BMY) Exceeds Q1 CY2026 Expectations

April 30, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q1 CY2026, with sales up 2.6% year on year to $11.49 bill...

Via StockStory

Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q1 Results Tomorrow

April 28, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting earnings this Thursday before market open. Here’s what investors should know. Bri...

Via StockStory

3 Healthcare Stocks That Pay You While You Wait for the Growth ↗

April 27, 2026

It may not seem like it at first, but these dividends are safe.

Via The Motley Fool

Topics Intellectual Property

3 Biotech Stocks That Could Benefit from the Patent Cliff ↗

April 27, 2026

Via MarketBeat

Topics Intellectual Property

Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗

April 27, 2026

This pharma stock is cheap for a reason.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.